STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRDL
  4. [6-K] Cardiol Therapeutics Inc. Current Report (Foreign Issuer)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) at Canaccord 46th Growth Conference

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Cardiol Therapeutics Inc., a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease, will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 11, 2026, at 9:00 a.m. EDT, with a live webcast available via its investor website.

The company highlights its lead small-molecule candidate CardiolRx™, which targets inflammasome pathway activation and is being evaluated in the MAVERIC Program for recurrent pericarditis, including a completed Phase II MAvERIC-Pilot study and an ongoing pivotal Phase III MAVERIC trial, and in the completed Phase II ARCHER study in acute myocarditis. Cardiol also notes U.S. FDA Orphan Drug Designation for CardiolRx in pericarditis and ongoing development of CRD-38, a subcutaneous formulation aimed at inflammatory heart disease, including heart failure.

Positive

  • None.

Negative

  • None.
Conference date and time August 11, 2026 at 9:00 a.m. EDT Timing of the Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference
Conference edition 46th Annual Growth Conference Name of the Canaccord Genuity investor conference in Boston
U.S. heart failure healthcare costs US$30 billion per year Associated healthcare costs in the United States for heart failure
MAvERIC-Pilot study phase Phase II Completed MAvERIC-Pilot study of CardiolRx in recurrent pericarditis
MAVERIC trial phase Phase III Ongoing pivotal MAVERIC trial of CardiolRx in recurrent pericarditis
ARCHER study phase Phase II Completed ARCHER study evaluating CardiolRx in acute myocarditis
Sudden cardiac death age reference 35 years of age Acute myocarditis noted as leading cause of sudden cardiac death under 35
Orphan Drug Designation regulatory
"The U.S. FDA has granted Orphan Drug Designation to CardiolRx™"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
recurrent pericarditis medical
"evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease"
Inflammation of the thin sac around the heart that comes back after a first episode. Like a door that keeps sticking shut even after being fixed, recurrent pericarditis involves repeated bouts of chest pain, fever, or fatigue that can require ongoing treatment, tests, or even procedures. Investors track it because recurrent disease affects healthcare spending, drug trial design, regulatory review, and the potential market for therapies aimed at preventing or managing flare-ups.
acute myocarditis medical
"studied CardiolRx™, specifically in acute myocarditis--an important cause of acute"
Acute myocarditis is a sudden inflammation of the heart muscle that can weaken the heart’s ability to pump and cause irregular rhythms, often requiring medical treatment or hospitalization. For investors, it matters because cases can affect employee or executive health, trigger product safety or clinical-trial concerns, increase medical and legal costs, and prompt regulatory scrutiny—similar to how a jammed pump can slow down an entire factory’s output and raise repair bills.
inflammasome pathway activation medical
"CardiolRx™ modulates inflammasome pathway activation, an intracellular innate immune"
A cascade in certain immune cells where protein complexes called inflammasomes act like an intracellular alarm system, activating enzymes that produce inflammatory signals (notably IL‑1β and IL‑18) and can trigger a form of cell death. Scientists target or measure this pathway because turning it on or off can drive disease processes, serve as a biomarker of drug effect, or create safety and regulatory considerations for therapies, much like flipping a building’s fire alarm can change how people respond.
subcutaneously administered medical
"developing CRD-38, a novel, subcutaneously administered drug formulation"
A subcutaneously administered treatment is given by injecting medication just under the skin into the fatty layer, like placing a small dose into a shallow pocket beneath the surface rather than into a muscle or a vein. For investors, this matters because such delivery can make therapies easier for patients to self-administer, reduce clinic visits, and affect manufacturing, packaging, and reimbursement, all of which influence market adoption and cost structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What event will Cardiol Therapeutics (CRDL) attend on August 11, 2026?
Cardiol Therapeutics will join a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 11, 2026, at 9:00 a.m. EDT, providing an update on its late-stage cardiovascular therapy programs.

How can investors access Cardiol Therapeutics' (CRDL) Canaccord fireside chat?
A live webcast of Cardiol Therapeutics' fireside chat will be accessible under "Events & Presentations" in the Investors section of the company’s website, allowing remote participants to follow the discussion in real time.

What is Cardiol Therapeutics' (CRDL) lead drug candidate CardiolRx?
CardiolRx™ is a small-molecule drug candidate that modulates inflammasome pathway activation and is being developed for pericarditis, myocarditis, and heart failure, targeting inflammation and fibrosis in these serious cardiovascular conditions.

What does the MAVERIC Program involve for Cardiol Therapeutics (CRDL)?
The MAVERIC Program evaluates CardiolRx™ in recurrent pericarditis and includes the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299), focusing on symptoms such as chest pain and reduced quality of life.

What did the ARCHER Program study for Cardiol Therapeutics (CRDL)?
The ARCHER Program comprised a completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in acute myocarditis, an important cause of acute and fulminant heart failure in young adults.

What is CRD-38 in Cardiol Therapeutics' (CRDL) pipeline?
CRD-38 is a novel, subcutaneously administered formulation being developed for inflammatory heart disease, including heart failure, a major cause of death and hospitalization with U.S. healthcare costs exceeding US$30 billion per year.

What regulatory status has CardiolRx received according to Cardiol Therapeutics (CRDL)?
The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis, recognizing the drug’s potential for a rare but serious inflammatory heart condition.

 

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[   ] Form 20-F     [X] Form 40-F

 

 

 
 

 

SUBMITTED HEREWITH

Exhibits

Exhibit   Description
     
99.1   News Release dated August 5, 2026 - Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  CARDIOL THERAPEUTICS INC.
  (Registrant)
     
Date: August 5, 2026 By: /s/ Christopher Waddick
    Christopher Waddick
  Title: Chief Financial Officer

 

 

EXHIBIT 99.1

 

 

 

 

 

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference

TORONTO, Aug. 5, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Boston, MA, on August 11, 2026, at 9:00 a.m. EDT.

Canaccord Genuity's 46th Annual Growth Conference

When: Tuesday, August 11 at 9:00 a.m. EDT.
Where: InterContinental Boston Hotel, in Griffin/Robinson

A live webcast of the Fireside Chat will be accessible under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/).

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.

The ARCHER Program also studied CardiolRx™, specifically in acute myocarditis--an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.

The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure--a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; and the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiol-therapeutics-to-participate-in-fireside-chat-at-canaccord-genuitys-46th-annual-growth-conference-302843548.html

SOURCE Cardiol Therapeutics Inc.

 

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2026/05/c2390.html

%CIK: 0001702123

For further information: For further information, please contact: Investor.relations@cardiolrx.com

CO: Cardiol Therapeutics Inc.

CNW 07:27e 05-AUG-26

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases